rotation.to
Following this device: dark.
Free account
rotation.to
Sign in / Request free access
Appearance
Following this device: dark.
Drag a card by its title · ⚙ to size, swap or remove

Who

Judith Dunn

Director

Company insider

Files Form 4 as: Director, Climb Bio; Officer, Fulcrum Therapeutics; Director, Seelos Therapeutics.

Every Form 4 they filed

In numbers

Trades disclosed
11
Buys
0
Sells
0
Bought
$0
Sold
$0
Companies
3
Companies where not an officer
2
First trade
15 May 2020
Last trade
5 Jun 2026
Last filed
8 Jun 2026

Companies traded

Where they are an officer
FULC Fulcrum TherapeuticsOfficer · Biotechnology · last 19 Jan 20220 buys · 0 sells
Everywhere else they filed: board seats, 10% stakes, other companies
CLYM Climb BioDirector · Biotechnology · last 5 Jun 20260 buys · 0 sells
Seelos TherapeuticsDirector · last 6 Jan 20210 buys · 0 sells

Activity over time

Not enough dated trades to draw.

Every trade

TradedCompanyWhatAmount
5 Jun 2026filed 8 Jun 2026CLYM Climb Biooption or derivative · BiotechnologySEC FORM 4 Code A—40,000 at $0.00filing
5 Jun 2026filed 8 Jun 2026CLYM Climb Biooption or derivative · BiotechnologySEC FORM 4 Code A—40,000 at $0.00filing
4 Jun 2025filed 5 Jun 2025CLYM Climb Biooption or derivative · BiotechnologySEC FORM 4 Code A—40,000 at $0.00filing
26 Jun 2024filed 28 Jun 2024CLYM Climb Biooption or derivative · BiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
18 May 2023filed 22 May 2023CLYM Climb Biooption or derivative · BiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
19 May 2022filed 1 Jun 2022CLYM Climb Biooption or derivative · BiotechnologySEC FORM 4 Code A—10,000 at $0.00filing
19 Jan 2022filed 21 Jan 2022FULC Fulcrum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—140,890 at $0.00filing
1 Apr 2021filed 2 Apr 2021FULC Fulcrum Therapeuticsoption or derivative · BiotechnologySEC FORM 4 Code A—215,000 at $0.00filing
6 Jan 2021filed 8 Jan 2021Seelos Therapeuticsoption or derivativeSEC FORM 4 Code A—16,000 at $0.00filing
15 May 2020filed 15 May 2020Seelos Therapeuticsoption or derivativeSEC FORM 4 Code A—24,000 at $0.00filing
15 May 2020filed 15 May 2020Seelos Therapeuticsoption or derivativeSEC FORM 4 Code A—16,000 at $0.00filing

News

No headline names them, or the companies they trade most, lately.

Sectors

No trade we could place in a sector.

Related people

Kevin Tang10% owner · 10% owner at Fulcrum Therapeutics, filing Form 4 there in the last year
Kate HavilandDirector · Director at Fulcrum Therapeutics, filing Form 4 there in the last year
James A. GeraghtyDirector · Director at Fulcrum Therapeutics, filing Form 4 there in the last year
Robert J. GouldDirector · Director at Fulcrum Therapeutics, filing Form 4 there in the last year
Rachel K. KingDirector · Director at Fulcrum Therapeutics, filing Form 4 there in the last year